AAA Oxford Immunotec closes IPO

Oxford Immunotec closes IPO

US-based Oxford Immunotec, a medical diagnostics company, has closed its initial public offering (IPO) with 5,360,000 shares priced at $13 to $15 per share under the ticker symbol “OXFD.”  The underwriters had the option to purchase up to 804,000 additional ordinary shares. The company had expected to raise around $63.8m which would have valued the company at $229.1m, but instead raised $62.8m.

J.P. Morgan and Piper Jaffray & Co served as lead underwriters.

Oxford has so far raised $107m in funding. Last year the company raised $28m in a venture round led by Imperial Innovations, and including the participation of US-based materials company the Dow Chemical Company and Kaiser Permanente Ventures, the corporate venturing unit of US-based healthcare group Kaiser Permanente.

US-based materials company the Dow Chemical Company and Kaiser Permanente Ventures, the corporate venturing unit of US-based healthcare group Kaiser Permanente, have invested $28m in Oxford Immunotec, a medical diagnostic company . – See more at: http://www.globalcorporateventuring.com/article.php/4037/oxford-immunotec-injected-with-28m#sthash.VryyGivy.dpuf
US-based materials company the Dow Chemical Company and Kaiser Permanente Ventures, the corporate venturing unit of US-based healthcare group Kaiser Permanente, have invested $28m in Oxford Immunotec, a medical diagnostic company . – See more at: http://www.globalcorporateventuring.com/article.php/4037/oxford-immunotec-injected-with-28m#sthash.VryyGivy.dpuf
US-based materials company the Dow Chemical Company and Kaiser Permanente Ventures, the corporate venturing unit of US-based healthcare group Kaiser Permanente, have invested $28m in Oxford Immunotec, a medical diagnostic company . – See more at: http://www.globalcorporateventuring.com/article.php/4037/oxford-immunotec-injected-with-28m#sthash.VryyGivy.dpuf

In 2010 New Leaf Ventures led a $26m D round. In 2007, the company raised $40m in its series C round of financing and in 2005 $7m in a B round with involvement from Prelude Trust, Quester Capital and The Dow Company.

Leave a comment

Your email address will not be published. Required fields are marked *